|Home||Internet of Things||Aerospace||Apparel||Energy||Defense||Health Care||Logistics||Manufacturing||Retail|
FDA RFID Drug Pilot Planned This Summer
The U.S. Food and Drug Administration has signed on to a six-month project with a technology firm, as well as drug companies and hospitals, to study the value of data captured from UHF RFID-tagged injectable drugs as they move from the point of manufacture to a patient.
Jul 30, 2019—
The U.S. Food and Drug Administration (FDA) plans to launch a pilot in August 2019, managed by a group of technology, drug and health-care companies, to measure the effectiveness of using RFID technology to improve drug traceability and verification in the supply chain. Pharmaceutical traceability technology firm Kit Check recommended the pilot to the FDA and is providing the testing of UHF RFID tag reads, as well as related data, in partnership with the Hackensack University Medical Center, Coral Gables Hospital, Nephron Pharmaceuticals and Novartis.
The six-month pilot will test an alternative technology for meeting the requirements of the FDA's Drug Supply Chain Security Act (DSCSA)—namely, RFID—with UHF tags applied to the packaging of drugs, which are read as they move through the supply chain and are compared against traditional 2D barcodes. The pilot will leverage both the 2D barcode monitoring technology commonly in use, as well as RFID, so both methods can be evaluated, compared and analyzed. The goal is to identify whether RFID could provide use cases for greater drug supply chain visibility, according to Kevin MacDonald, Kit Check's CEO and co-founder.
"With RFID," MacDonald says, "we're doing this at a more detailed level than 2023 regulations required." For instance, with barcodes, companies typically track goods by the case, scanning the barcode on each case as it is transported to a hospital and is provided to patients. However, that provides no item-level traceability, he notes. "With RFID, we're tracking every single vial, every step of the way."
The test consists of attaching adhesive UHF RFID labels, provided by Avery Dennison, to vials of a variety of injectable drugs, as well as pre-filled syringes, according to the FDA's requirements. The labels will be attached at the point of manufacture and will then be read at multiple points along the supply chain, through the distribution center and to the hospital. The readers used to read the tags before the product reaches the latter will be a combination of off-the-shelf devices, MacDonald says, while Kit Check's own RFID-enabled scanning stations will be deployed at hospitals.
Each tag's unique ID number will be linked to the drug's batch and lot numbers, as well as to its date of manufacture and expiration date, and this information will be stored in Kit Check's software. The tag will be read at the point of shipping and again at the receiving hospital. At the same time, barcode scans will be collected and stored as part of the electronic data exchange.
Kit Check predicts the RFID-based data could provide more granular details regarding products and their history, as well as prove their authenticity. For instance, MacDonald says, with the unique ID captured and linked to a particular lot number and other related data, in the event that a drug is recalled, the software will enable supply chain members to identify where each vial of a recalled product is located. It will also allow an alert to be sent to the hospital that may have that vial onsite, so that it will not be administered to a patient.
Login and post your comment!
Not a member?
Signup for an account now to access all of the features of RFIDJournal.com!
SEND IT YOUR WAY
RFID JOURNAL EVENTS
ASK THE EXPERTS
Simply enter a question for our experts.
|RFID Journal LIVE!||RFID in Health Care||LIVE! LatAm||LIVE! Brasil||LIVE! Europe||RFID Connect||Virtual Events||RFID Journal Awards||Webinars||Presentations|